Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers

NCT02351765 is registered in ClinicalTrials.gov with The Christie NHS Foundation Trust as lead sponsor.

NCT NCT02351765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02351765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers
Lead sponsor
The Christie NHS Foundation Trust
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
March 31, 2019
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ampullary cancer, biliary tract cancer, cholangiocarcinoma, gallbladder cancer